EGFR and c-Src Antisense Oligodeoxynucleotides with PAMAM Denderimers Inhibit HT-29 Proliferation

The blocking of the oncogenic pathways in different malignancies can contribute to molecularly targeted therapeutics and has clinical benefits. c-Src is arguably the oldest known oncogene and most important proto-oncogen in the development and progression of colon cancer. It is often over-expressed and activated in the number of human cancers such as colon, prostate, brain, lung, breast, ovarian, liver and pancreas carcinoma (Talamonti et al., 1993; Summy, 2005; Finn, 2008; Lieu and Kopetz, 2010).Src proto oncogen, has a key role in cellular pathways, such as migration, survival, motility, adhesion, angiogenesis, invasion, immune function and regulation of proliferation (Ellis, 1998; Summy and Gallick, 2003) Furthermore, c-Src has high kinase activity and protein level in the progression stage of colorectal cancer to hepatic metastases (Talamonti et al., 1993). Multiple signaling pathways are correlated with c-Src family